Navigation Links
VetStem Biopharma and PALL Life Sciences announce a clinical research/technology distribution agreement for Pall’s Veterinary Platelet Enhancement Therapy system V-PET™
Date:11/13/2015

“VetStem was a logical choice, given that they are the stem cell leader in the US and Canadian markets. We share a commitment to ongoing research in the life science fields.”, stated Mr. Antoine, Pall Sales Manager, Americas Cell Therapy.

“The V-PET™ platelet enhancement therapy system complements perfectly our current portfolio of regenerative medicine solutions”, said Dr Nahama, President and Chief Commercial Officer for VetStem. “It is validated for use in dogs and horses. Because the technology is gravity filtration based, it does not require a centrifuge to process samples. Any veterinarian in the field, at the patients’ home or in a hospital setting can have enhanced platelet therapy ready for injection in about 30 minutes.”

“Stem Cell Therapy and enhanced platelet therapy are highly complementary depending on the disease state and the specific client needs”, added Dr Nahama.

Platelet therapy promotes healing when the body requires help to kick start its natural internal repair processes. Platelets contain a variety of growth factors that, once released, attract progenitor cells, enhance wound healing and stimulate tissue regeneration. Since the animal is the donor and recipient of the therapy, the safety profile (autologous therapy) is very favorable.

The most common uses of platelet therapy are for indications such as hard to heal wounds, tendon and ligament injuries, as well as joint disease (osteoarthritis).

V-PET™ will be available to US and Canada veterinarians directly through VetStem Biopharma, or selected distributors, starting late November 2015.

About VetStem Biopharma
VetStem Biopharma is a veterinarian lead company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego (California), currently offers veterinarians an autologous stem cell processing service (from patients’ own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 12 years and 11,000 patients treated by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality beyond the realm of research. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. The company’s stated mission being “to extend and enhance the lives of animals by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases”. In addition to its’ own portfolio of patents, VetStem holds exclusive global veterinary licenses to a portfolio of over 55 issued patents in the field of regenerative medicine.

Contact
Kristi Hauta
VetStem Biopharma
khauta(at)vetstem(dot)com

About PALL Life Sciences
Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industrial manufacturing. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company’s engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation serves customers worldwide. For more information, please visit: http://www.pall.com, or follow us on social media at: Facebook; Google+; LinkedIn ; Twitter; and YouTube.

Contact
Mary-Shea Rozsypal
Director, Global Marketing Communications
Pall Life Sciences
Email: Mary-Shea_Rozsypal(at)pall(dot)com

Read the full story at http://www.prweb.com/releases/2015/11/prweb13079576.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2018)... ... August 16, 2018 , ... Ambry Genetics Corporation (“Ambry”), ... project were published today in JAMA Oncology, identifying new and confirming known hereditary ... , Every year hereditary breast cancer affects more than 20,000 women while hereditary ...
(Date:8/14/2018)... ... August 14, 2018 , ... The growing interest ... of the Chinese Association of Orthopaedic Surgeons (CAOS) held in partnership with the ... Development , Beijing, and Invibio Biomaterial Solutions partnered to demonstrate the ...
(Date:8/9/2018)... ... August 08, 2018 , ... InTouchMD , the leading provider of data ... be exhibiting at Biotech Week Boston , September 4th – 7th at Hynes ... platform, healthcare’s most powerful all in one marketing solution. Pulse is a multi-use ...
(Date:8/9/2018)... ... August 09, 2018 , ... Simpson ... construction (AEC) experts with building owners and managers for a full-day discussion on ... Construct symposium comes to Boston for the first time on Thursday, 13 September ...
Breaking Biology Technology:
(Date:8/9/2018)... ... August 08, 2018 , ... ... to invest in disruptive technology and healthcare companies, has invested in a sought-after ... stealth mode. , CRISPR Technology and Mammoth Biosciences , The biotech company ...
(Date:8/7/2018)... DIEGO (PRWEB) , ... August 07, 2018 , ... ... that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, “Synthetic ... Bioorganic & Medicinal Chemistry. The paper prominently features use of Agile R100, described ...
(Date:8/1/2018)... ... 2018 , ... Dr. Asher Kimchi, Founder and Chairman of the International ... Awards at the 23rd World Congress on Heart Disease held in Boston, MA, USA. ... the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Chairman Dr. John A. ...
Breaking Biology News(10 mins):